Cardiff Oncology Files Q3 2024 10-Q

TL;DR

Cardiff Oncology dropped its Q3 10-Q. Check financials.

AI Summary

Cardiff Oncology, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results and operational updates. Key financial figures and strategic developments are detailed within the filing, which covers the third quarter of 2024.

Why It Matters

This filing provides investors with the latest financial performance and operational status of Cardiff Oncology, crucial for understanding the company's trajectory in the biopharmaceutical sector.

Risk Assessment

Risk Level: medium — As a biopharmaceutical company, Cardiff Oncology faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

• Q3 2024 — Reporting Period (The filing covers the third quarter of 2024.)
• 12/31 — Fiscal Year End (The company's fiscal year ends on December 31st.)

Key Players & Entities

• Cardiff Oncology, Inc. (company) — Filer of the 10-Q
• 20240930 (date) — End of reporting period
• 20241107 (date) — Filing date
• SAN DIEGO (location) — Company's business and mailing address city
• Trovagene, Inc. (company) — Former company name

FAQ

Filing Documents

• crdf-20240930.htm (10-Q) — 1491KB
• crdf-ex31_1.htm (EX-31.1) — 13KB
• crdf-ex31_2.htm (EX-31.2) — 13KB
• crdf-ex32_1.htm (EX-32.1) — 6KB
• crdf-ex32_2.htm (EX-32.2) — 6KB
• 0000950170-24-123242.txt ( ) — 5825KB
• crdf-20240930.xsd (EX-101.SCH) — 663KB
• crdf-20240930_htm.xml (XML) — 1118KB

Financial Statements (unaudited)

Financial Statements (unaudited) 3 Condensed Balance Sheets 3 Condensed Statements of Operations 4 Condensed Statements of Comprehensive Loss 5 Condensed Statements of Stockholders' Equity 6 Condensed Statements of Cash Flows 8 Notes to Condensed Financial Statements 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 22 Item 4.

Controls and Procedures

Controls and Procedures 23 PART II OTHER INFORMATION 24 Item 1.

Legal Proceedings

Legal Proceedings 24 Item 1A.

Risk Factors

Risk Factors 24 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 24 Item 3. Defaults Upon Senior Securities 24 Item 4. Mine Safety Disclosures 24 Item 5. Other Information 24 Item 6. Exhibits 24

SIGNATURES

SIGNATURES 25 2 Table of Contents

FIN ANCIAL INFORMATION

PART I. FIN ANCIAL INFORMATION

FINANCIAL STAT EMENTS

ITEM 1. FINANCIAL STAT EMENTS CARDIFF ONCOLOGY, INC. CONDENSED BALANC E SHEETS (in thousands, except par value) (Unaudited) September 30, 2024 December 31, 2023 Assets Current assets: Cash and cash equivalents $ 13,038 $ 21,655 Short-term investments 44,629 53,168 Accounts receivable and unbilled receivable 618 288 Prepaid expenses and other current assets 1,047 2,301 Total current assets 59,332 77,412 Property and equipment, net 993 1,238 Operating lease right-of-use assets 1,304 1,708 Other assets 1,267 1,279 Total Assets $ 62,896 $ 81,637 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 4,643 $ 1,966 Accrued liabilities 7,175 7,783 Operating lease liabilities 707 691 Total current liabilities 12,525 10,440 Operating lease liabilities, net of current portion 979 1,458 Total Liabilities 13,504 11,898 Commitments and contingencies (Note 6) Stockholders' equity Preferred stock, 20,000 shares authorized; 277 designated as Series A Convertible Preferred Stock; 61 shares outstanding at September 30, 2024 and December 31, 2023 with liquidation preference of $ 1,086 and $ 1,068 at September 30, 2024 and December 31, 2023, respectively — — Common stock, $ 0.0001 par value, 150,000 shares authorized; 48,731 and 44,677 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 5 4 Additional paid-in capital 421,697 409,343 Accumulated other comprehensive gain (loss) 82 ( 67 ) Accumulated deficit ( 372,392 ) ( 339,541 ) Total stockholders' equity 49,392 69,739 Total liabilities and stockholders' equity $ 62,896 $ 81,637 See accompanying notes to the unaudited condensed financial statements. 3 Table of Contents CARDIFF ONCOLOGY, INC. CONDENSED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (Unaudited) Three Mon

View Full Filing

View this 10-Q filing on SEC EDGAR